Pluri Q3 2024 Earnings Report $4.34 +0.02 (+0.56%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings History Pluri EPS ResultsActual EPS-$1.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APluri Revenue ResultsActual Revenue$0.07 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APluri Announcement DetailsQuarterQ3 2024Date5/9/2024TimeN/AConference Call ResourcesPLUR Earnings History Pluri Earnings HeadlinesPluri Inc. granted extension to regain Nasdaq complianceJanuary 21 at 6:06 PM | msn.comCritical Analysis: Pluri (NASDAQ:PLUR) and Adverum Biotechnologies (NASDAQ:ADVM)January 19 at 2:10 AM | americanbankingnews.com2025: Crypto Opportunities You Can’t Afford to MissCryptocurrencies are once again gaining incredible momentum, and savvy investors are positioning themselves to capitalize on this surge in 2025. The question is—will you be among them? With groundbreaking advancements and increasing institutional adoption on the horizon, there's never been a better time to explore the potential gains in crypto. What’s Fueling the Crypto Comeback?January 21, 2025 | Darwin (Ad)Pluri congratulates Mesoblast, CEO on FDA approval of MSC-based therapyDecember 20, 2024 | markets.businessinsider.comPluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host DiseaseDecember 19, 2024 | globenewswire.comPluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025December 10, 2024 | markets.businessinsider.comSee More Pluri Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email. Email Address About PluriPluri (NASDAQ:PLUR), a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.View Pluri ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025)ICICI Bank (1/22/2025)Johnson & Johnson (1/22/2025)Kinder Morgan (1/22/2025)Procter & Gamble (1/22/2025)Progressive (1/22/2025)Travelers Companies (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
